CRN09682 for Neuroendocrine Tumors
(BRAVESST2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines a new treatment, CRN09682, for individuals with certain tumors, such as neuroendocrine tumors (NETs) and other solid growths. The trial aims to assess the safety and effectiveness of this treatment and determine the optimal dose. It involves different groups, focusing on tumors related to the pancreas, other neuroendocrine areas, and more. Suitable candidates have tumors that cannot be surgically removed and have shown growth on scans. As a Phase 1 trial, this research seeks to understand how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does mention that you cannot use anticancer agents within certain timeframes before starting the study drug. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that CRN09682 is likely to be safe for humans?
Research has shown that CRN09682 is in the early stages of testing, focusing on its safety and tolerability. Currently, detailed information on side effects from these studies is unavailable. The trial aims to determine the treatment's safety by assessing any serious side effects and how well patients manage different doses. As the trial is just beginning, researchers are closely monitoring safety to ensure it is generally well-tolerated. This treatment is not yet approved for any conditions, so safety information is still being collected.12345
Why do researchers think this study treatment might be promising for neuroendocrine tumors?
Researchers are excited about CRN09682 because it offers a new approach to treating neuroendocrine tumors (NETs), which include pancreatic and non-pancreatic NETs, as well as neuroendocrine carcinoma. Unlike traditional treatments such as somatostatin analogs or targeted therapies like everolimus and sunitinib, CRN09682 is being tested across multiple dosing strategies, including dose escalation and expansion cohorts. This method allows researchers to fine-tune the dosage for optimal effectiveness and safety, potentially offering a more personalized treatment option. Additionally, the unique dosing schedule of administering multiple dose levels every three weeks (Q3W) could lead to improved outcomes and patient experiences.
What evidence suggests that CRN09682 might be an effective treatment for neuroendocrine tumors?
Research has shown that CRN09682 is under study as a potential treatment for neuroendocrine tumors in this trial. This drug targets a specific part of the tumor known as somatostatin receptor 2. Early results are promising, particularly for patients with high levels of the protein DLL3, with about 40% experiencing tumor shrinkage. Overall, about 67% of patients in studies have shown some positive response to similar treatments. While further research is necessary, these early findings suggest that CRN09682 could be a promising option for individuals with neuroendocrine tumors.16789
Are You a Good Fit for This Trial?
This trial is for people with certain types of tumors that show up on special scans (SST2-expressing NENs and other solid tumors). Participants should be able to perform daily activities with ease or have only slight limitations, and must have a confirmed diagnosis of advanced or metastatic neuroendocrine carcinoma, pancreatic cancer, carcinoid tumor, or similar conditions that are getting worse.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive multiple dose levels of CRN09682 administered every 3 weeks to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs)
Dose Expansion
Additional participants are enrolled at the expansion dose to further assess safety, tolerability, pharmacokinetics (PK), and antitumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CRN09682
Trial Overview
The study tests CRN09682's safety and effectiveness. It has two parts: first, finding the highest dose patients can take without serious side effects (Dose Escalation Phase), then giving more people this dose to see how well it works and what side effects occur (Expansion Phase).
How Is the Trial Designed?
5
Treatment groups
Experimental Treatment
Other Solid Tumors
Neuroendocrine Carcinoma (NEC)
Non-Pancreatic NET
Pancreatic Neuroendocrine Tumor (NET)
Multiple Dose Levels administered Q3W
Find a Clinic Near You
Who Is Running the Clinical Trial?
Crinetics Pharmaceuticals Inc.
Lead Sponsor
Citations
Crinetics Announces First Patient Dosed in Phase 1/2 Trial ...
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin ...
NCT07129252 | A Study to Investigate Safety and ...
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in ...
Clinical Trial Details
Metastatic or locally advanced SST2-positive neuroendocrine neoplasms in adults - A Study to Investigate Safety and Effectiveness of CRN09682 in ...
News Details
CRN09682 is an investigational, potentially first-in-class, non-radioactive, nonpeptide drug conjugate (NDC) linking a somatostatin receptor 2 ...
Clinical Trials Aim to Advance the Future of ...
The results show encouraging signs, especially in patients whose tumors have high levels of DLL3, where 40% saw their tumors shrink. Overall, 67 ...
Crinetics to Highlight Neuroendocrine Tumor Research ...
CRN09682 is an investigational, potentially first-in-class, non-radioactive, nonpeptide drug conjugate (NDC) linking a somatostatin receptor 2 ( ...
7.
clinicaltrialvanguard.com
clinicaltrialvanguard.com/news/first-patient-dosed-in-crinetics-neuroendocrine-tumor-trial/First Patient Dosed in Crinetics' Neuroendocrine Tumor Trial
CRN09682 will need to demonstrate a tolerable DLT window, manageable peripheral neuropathy and hematologic safety, and clear signs of target- ...
Crinetics Announces First Patient Dosed in Phase 1/2 Trial ...
CRN09682 is an investigational, first-in-class, non-radioactive, nonpeptide drug conjugate (NDC) linking a somatostatin receptor 2 (SST2) ...
9.
ctv.veeva.com
ctv.veeva.com/study/a-study-to-investigate-safety-and-effectiveness-of-crn09682-in-participants-with-sst2-expressing-nenA Study to Investigate Safety and Effectiveness of CRN09682 ...
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.